JP2024540839A - Ｋｒａｓ ｇ１２ｄ阻害剤とｓｈｐ－２阻害剤との併用療法 - Google Patents

Ｋｒａｓ ｇ１２ｄ阻害剤とｓｈｐ－２阻害剤との併用療法 Download PDF

Info

Publication number
JP2024540839A
JP2024540839A JP2024520702A JP2024520702A JP2024540839A JP 2024540839 A JP2024540839 A JP 2024540839A JP 2024520702 A JP2024520702 A JP 2024520702A JP 2024520702 A JP2024520702 A JP 2024520702A JP 2024540839 A JP2024540839 A JP 2024540839A
Authority
JP
Japan
Prior art keywords
inhibitor
shp
alkyl
kras
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540839A5 (https=
JPWO2023059598A5 (https=
Inventor
ハリン，ジル
クリステンセン，ジェームズ・ゲイル
ボウカット，ビッキー
オルソン，ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of JP2024540839A publication Critical patent/JP2024540839A/ja
Publication of JP2024540839A5 publication Critical patent/JP2024540839A5/ja
Publication of JPWO2023059598A5 publication Critical patent/JPWO2023059598A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024520702A 2021-10-05 2022-10-04 Ｋｒａｓ ｇ１２ｄ阻害剤とｓｈｐ－２阻害剤との併用療法 Pending JP2024540839A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252561P 2021-10-05 2021-10-05
US63/252,561 2021-10-05
PCT/US2022/045623 WO2023059598A1 (en) 2021-10-05 2022-10-04 Combination therapies of kras g12d inhibitors with shp-2 inhibitors

Publications (3)

Publication Number Publication Date
JP2024540839A true JP2024540839A (ja) 2024-11-06
JP2024540839A5 JP2024540839A5 (https=) 2025-10-10
JPWO2023059598A5 JPWO2023059598A5 (https=) 2025-10-10

Family

ID=85803689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520702A Pending JP2024540839A (ja) 2021-10-05 2022-10-04 Ｋｒａｓ ｇ１２ｄ阻害剤とｓｈｐ－２阻害剤との併用療法

Country Status (6)

Country Link
US (1) US20240423984A1 (https=)
EP (1) EP4412719A4 (https=)
JP (1) JP2024540839A (https=)
KR (1) KR20240073114A (https=)
CN (1) CN118401254A (https=)
WO (1) WO2023059598A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024543879A (ja) * 2021-11-24 2024-11-26 メルク・シャープ・アンド・ドーム・エルエルシー Ｋｒａｓ変異型タンパク質の小分子阻害剤
JP2025518795A (ja) * 2022-06-03 2025-06-19 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法
JP2025523101A (ja) * 2022-07-12 2025-07-17 メッドシャイン ディスカバリー インコーポレイテッド ピペラジン架橋置換複素環ピリミジン系化合物
AU2024329738A1 (en) * 2023-08-22 2026-04-09 Sanofi 2-(3,8-diazabicyclo[3.2.1]octan-3-yl)-1,3,5-triazine derivatives as kras g12d inhibitors for the treatment of cancer
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024357850A1 (en) 2023-10-09 2026-04-23 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2026080796A1 (en) * 2024-10-11 2026-04-16 Mirati Therapeutics, Inc. Mrtx1133 capsule pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021076655A1 (en) 2019-10-15 2021-04-22 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
EP4225383A4 (en) * 2020-10-08 2024-12-11 Kumquat Biosciences Inc. MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES
WO2022187528A1 (en) * 2021-03-05 2022-09-09 Nikang Therapeutics, Inc Quinazoline amine derivatives as kras inhibitors
WO2023284730A1 (en) 2021-07-14 2023-01-19 Nikang Therapeutics, Inc. Alkylidene derivatives as kras inhibitors

Also Published As

Publication number Publication date
US20240423984A1 (en) 2024-12-26
CN118401254A (zh) 2024-07-26
WO2023059598A1 (en) 2023-04-13
EP4412719A4 (en) 2025-08-13
EP4412719A1 (en) 2024-08-14
KR20240073114A (ko) 2024-05-24

Similar Documents

Publication Publication Date Title
JP7546549B2 (ja) 組み合わせ療法
JP2025098159A (ja) 組み合わせ療法
JP2024537140A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤とｓｏｓ１阻害剤との併用療法
JP2024540839A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤とｓｈｐ－２阻害剤との併用療法
JP2025000630A (ja) 組み合わせ療法
JP2025000632A (ja) 組み合わせ療法
JP2025000629A (ja) 組み合わせ療法
JP2024537136A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤と汎ＥｒｂＢファミリー阻害剤との併用療法
HK40109896A (zh) Kras g12d抑制剂与shp-2抑制剂的组合疗法
JP2025531491A (ja) 併用療法
HK40109895A (zh) Kras g12d抑制剂与sos1抑制剂的组合疗法
HK40059386A (zh) 组合疗法
EA044829B1 (ru) Способы комбинированной терапии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251002